Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-077-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- April 12, 1990 to May 28, 1990
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 406-077-0
- EC Name:
- -
- Molecular formula:
- Hill formula: C53H29Cl2Cu2K3N18Na4O21S5
- IUPAC Name:
- dicopper(2+) tripotassium tetrasodium 2-{[({2-[3-({4-[(3-{[4-({3-[({[2-(2-carboxylato-5-sulfonatophenyl)diazen-1-yl](phenyl)methylidene}amino)azanidyl]-2-oxido-5-sulfonatophenyl}amino)-6-chloro-1,3,5-triazin-2-yl](methyl)amino}-4-sulfonatophenyl)amino]-6-chloro-1,3,5-triazin-2-yl}amino)-2-oxido-5-sulfonatophenyl]hydrazin-2-id-1-ylidene}(phenyl)methyl)imino]amino}-4-sulfonatobenzoate
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Standard test system for this kind of study
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. Karl Thomae GmbH, Biberach/Riss, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 42 d
- Weight at study initiation: mean weight of
- 190 (100 - 201) g for the males
- 146 (140 - 155) g for the females.
- Fasting period before study: no
- Housing: single, type DK III stainless steel wire cages supplied by BECKER & Co., Castrop-Rauxel, Germany
- Diet (e.g. ad libitum): ground Kliba maintenance diet rat/mouse/hamster, 343 meal, supplied by Klingentalmühle AG, CH-4303 Kaiseraugst, Switzerland, ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 10 d
DETAILS OF FOOD AND WATER QUALITY:
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: April 12, 1990 to May 28, 1990
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- - PREPARATION OF DOSING SOLUTIONS:
dissolved in double distilled water
The test substance was weighed in for the dose group and made up to the measuring mark, by adding distilled water, and subsequently it was brought into solution using an Ultraturrax. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability of the test substance in the vehicle over a period of 4 hours was verified by Project No.: 10A0796/891270. The homogeneity of the test substance preparations were verified analytically by Project No. 1150796/89062.
One sample of each concentration obtained at the start of the study was sent to the analytical laboratory for determination of the correctness of the concentration of the test substance preparations.
The analyses were carried out in the analytical laboratories of BASF Aktiengesellschaft - Duration of treatment / exposure:
- 29 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- control and high dose: 10
low and mid-dose: 5 - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The LD50 value for rats after oral administration was > 2200 mg/kg body weight.
The 2-week test administration by gavage (11 x p.o.) to male and female Wistar rats at a dose of 1000 mg/kg body weight in both sexes led to no disturbance of the general state of the animals. The body weight change and feed consumption were unremarkable. The hematological and clinicochemical examinations carried out at the end of administration period resulted, in addition to a slightly decreased triglyceride values in the females, in no values deviating from normal. At necropsy, the males of the 1000 mg/kg body weight group showed a slightly reduced absolute and relative liver weight. In the males and females of the test group, both the kidneys as well as the contents of the stomach and intestinal tract were colored by the test substance. There were other gross-pathological changes.
Therefore, the following doses were selected for the 4-week administration period:
100 mg/kg body weight: as the expectable no adverse effect level
300 mg/kg body weight: as the intermediate concentration
1000 mg/kg body weight: as the concentration with expectable toxic effects
- Rationale for animal assignment (if not random): The male and female animals, separated by sex, were dis-tributed according to weight among the individual test groups before the start of the administration period. The list of randomization instructions was compiled with a computer (laboratory data processing, Department of Toxicology, BASF Aktiengesellschaft)
- Rationale for selecting satellite groups: to determine whether effects seen are reversible
- Post-exposure recovery period in satellite groups: 14 days in control and high-dose groups
- Section schedule rationale (if not random): randomised
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice (Mondays to Fridays) and once a day (Saturdays, Sundays and on public holidays)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION: Yes
- Time schedule for examinations: weekly
WATER CONSUMPTION: Yes
- Time schedule for examinations: daily by visual inspection
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes
- Time schedule for collection of blood: in the morning of day 26 or 43
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: 5/sex/group
- Parameters examined.:
- leukocytes
- erythrocytes
- hemoglobin
- hematocrit
- mean corpuscular volume
- mean corpuscular hemoglobin
- mean corpuscular hemoglobin concentration
- platelets
- thromboplastin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: in the morning of day 26 or 43
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: 5/sex/group
- Parameters examined.:
- alanine aminotransferase
- aspartate aminotransferase
- alkaline phosphatase
- serum-gamma-glutamyltransferase
- potassium
- chloride
- inorganic phosphate
- calcium
- urea
- creatinine
- glucose
- total bilirubin
- total protein
- albumin
- globulins
- triglycerides
- cholesterol
- magnesium
URINALYSIS: Yes
- Time schedule for collection of urine: the individual animals were transferred to metabolism cages and urine was collected overnight at 4°C on days 26 or 40. The urine samples were evaluated in a randomized sequence.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters examined:
- volume
- appearance
- nitrite
- pH
- protein
- glucose
- ketones
- urobilinogen
- bilirubin
- blood
- specific gravity
- sediment
NEUROBEHAVIOURAL EXAMINATION: Not specified
- Time schedule for examinations:
- Dose groups that were examined:
- Battery of functions tested: sensory activity / grip strength / motor activity / other:
IMMUNOLOGY: No
- Time schedule for examinations:
- How many animals:
- Dose groups that were examined:
- Parameters checked in table [No.?] were examined.
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- The KRUSKAL-WALLIS one way analysis of variance by ranks.
In: SIEGEL, S. (1956): Non-parametric Statistics for the behavioral sciences, pp. 184-194, McGraw-Hill Book Company, New York, Toronto, London
The MANN-WHITNEY U test
In: SIEGEL, S. (1956): Non-parametric Statistics for the behavioral sciences, pp. 116-127, McGraw-Hill Book Company, New York, Toronto, London
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Details on results:
- Neither premature mortalities nor clinical signs of toxicity
occurred. Faeces were discoloured blue among
the animals from the medium and high-dose groups. This effect proved to be reversible during the recovery phase.
Haematologically and clinico-chemically, there were no toxicologically relevant changes.
Morphologically, there was blue discolouration of the mucosa in the gastro-intestinal tract of the animals from the medium and high-dose groups. In addition, among the female animals, the relative kidney weights were elevated as were some of the absolute kidney weights in the follow-on observation period. Macroscopically, the kidneys of the animals from the high-dose group were coloured due to the dye. This observation also resulted for the mesenteric lymph nodes at the end of the follow-on observation period.
Pathohistologically, there were no changes. The changes which were detected were assessed as being exclusively deposition and excretion or temporary deposition (lymphogenic drainage) of the dye and were not regarded as toxicologically relevant.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on the results obtained during this oral toxicity study, the "no adverse effect level" of Reaktivblau 1463 is above 1000 mg/kg body weight.
- Executive summary:
Reaktivblau 1463 was administered by gavage to 3 groups, each of 5 male and 5 female Wistar rats, for 29 consecutive days, at 3 dose levels. A control group of 5 male and 5 female rats was dosed with vehicle alone. Two satellite groups, each of 5 males and 5 females, were treated with the high dose (dose of test group 3) or the vehicle alone also for 29 consecutive applications and then maintained without treatment for a further 14 days.
The doses were 100 mg/kg body weight, 300 mg/kg body weight and 1000 mg/kg body weight.
Feed consumption and body weight were determined weekly. Water consumption and the state of health was checked each day and once a week the Wistar rats were inspected and palpated. During the study period, the appearance of clinical signs was checked.
Toward the end of the administration period, a urine examination, a clinicochemical and hematological examination were carried out. Toward the end of the recovery period these examinations were also performed for the satellite groups.
All animals were assessed by gross pathology, followed by a histopathological examination.
Results:
Feed consumption: No treatment-related differences in feed consumption were noted during the study.
Body weight: Body weight in test animals was comparable with that seen in controls.
Water consumption: No overt differences were detected.
Clinical signs: No clinically observable signs of toxicity were detected in test or control animals. Blue faeces were seen 300 mg/kg body weight and more marked (deep blue) in test at 1000 mg/kg body weight; but this regressed during the 14-day treatment-free period.
Mortality: There were no deaths during the study period.
Clinical chemistry and haematology: There were no changes in the clinical chemistry and haematology parameters measured which could be considered toxicologically significant.
Urinalysis: No treatment-related changes were detected.
The application of the test substance led to blue-green discoloration of the contents of the stomach and the intestinal tract of most rats in groups 2 (300 mg/kg body weight) and 3 (1000 mg/kg body weight).
Blue-green discoloration was observed in the kidneys of male and female rats of group 3 and most females of group 2. The discoloration of the kidneys persisted after a recovery period of 2 weeks; however, the colour had changed to green-brown. At the end of the recovery period the mesenteric lymph nodes of the animals of the 1000 mg/kg body weight group were discoloured. In the latter organ, no discoloration was seen at the animals of the main groups.
The relative weights of kidneys (related to body weight) of the females of main groups 2 and 3 showed significant increases. At the end of the recovery period the absolute kidney weight was significantly increased.
Histopathology: No treatment-related changes were detected.
CONCLUSION
The observed statistically significant increases of the organ weights in the main group and in the recovery groups do not represent a treatment-related effect as no clear dose-response relationship was observed.
The discolorations in the kidneys and in the mesenteric lymph nodes did not result in microscopic organ lesions relatable to it, so that it is interpreted only as a physical property of the absorbed test article.
Based on the results obtained during this oral toxicity study, the "no adverse effect level" of Reaktivblau 1463 is above 1000 mg/kg body weight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.